CD19 and neoplasm: Fousek et al. reported that CAR-T cells targeting these three antigens simultaneously can effectively eliminate tumor cells that have relapsed and become CD19-negative after CD19 CAR-T treatment; these, CAR-T cells can still form effective immune synapses with tumor cells [83].